Results 21 to 30 of about 3,073 (139)

DEVELOPMENT AND VALIDATION OF SPECTROPHOTOMETRIC METHOD FOR THE DETERMINATION OF DPP-4 INHIBITOR, SITAGLIPTIN, IN ITS PHARMACEUTICAL PREPARATIONS

Eclética Química, 2018
A simple, sensitive and reproducible spectrophotometric method was developed for the determination of sitagliptin phosphate in bulk and in pharmaceutical formulations. The proposed method is based on condensation of the primary amino group of sitagliptin
C. Bala Sekaran, A. Prameela Rani
doaj   +1 more source

A Simple and Sensitive HPTLC Method for Simultaneous Determination of Metformin Hydrochloride and Sitagliptin Phosphate in Tablet Dosage Form

Journal of Chemistry, 2013
A simple, rapid, and precise high-performance thin-layer chromatographic (HPTLC) method for simultaneous estimation of two antidiabetic drugs, metformin hydrochloride and sitagliptin phosphate, in tablet dosage form has been developed and validated ...
Darshana K. Modi, Punit B. Parejiya, Bhavesh H. Patel   +2 more
doaj   +1 more source

Formulation And In-vitro Evaluation Of Bilayer Tablets Of Sitagliptin Phosphate

, 2021
The aim of this work was to plan mucoadhesive bilayered buccal tablets of Sitagliptin Phosphate. Sitagliptin Phosphate is the phosphate salt type of sitagliptin, an orally accessible, serious, beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP4) with hypoglycemic movement.
Mayur Aware, Gondkar, Sheetal, Rishikesh Bachhav   +2 more
openaire   +1 more source

Is Transdermal Delivery Potential Route for Sitagliptin Phosphate: The pH Control Effect

Future Journal of Pharmaceuticals and Health Sciences, 2023
The objective of this study is to predict transdermal delivery as a potential route for sitagliptin phosphate. The partition coefficient of sitagliptin phosphate was measured in a chloroform - buffer system using the shake flask method at room temperature, and the analysis was performed under different pH conditions.
{\\"name\\":\\"Chika J Mbah\\",\\"email\\":\\"bosky24.ec@gmail.com\\",\\"affiliation\\":\\"Depart, {\\"name\\":\\"William O Obonga\\",\\"email\\":\\"bosky24.ec@gmail.com\\",\\"affiliation\\":\\"Depa, {\\"name\\":\\"Chidinma M Ekebor\\",\\"email\\":\\"bosky24.ec@gmail.com\\",\\"affiliation\\":\\"Depa   +2 more
openaire   +1 more source

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study [PDF]

Endocrinology and Metabolism, 2016
BackgroundThe use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been ...
Jaehyun Bae, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Hye Jin Wang, Myoung Soo Kim, Yu Seun Kim, Joong-Yeol Park, Eun Seok Kang   +8 more
doaj   +1 more source

Simultaneous HPLC determination of remdesivir and dexamethasone in the presence of metformin, sitagliptin, and glimepiride in a synthetic mixture and spiked human plasma [PDF]

Pharmacia
The COVID-19 pandemic has raised many questions regarding the control and therapy of type 2 diabetes and the higher risk of severe disease progression. One of the therapeutic regimens used in moderate and severe cases of COVID-19, endorsed by the World ...
Stanislav Bozhanov, Miglena Smerikarova, Vania Maslarska   +2 more
doaj   +3 more sources

Formulation, Development and Characterization of Transdermal Patches of Sitagliptin Phosphate

Journal of Drug Delivery and Therapeutics, 2019
Sitagliptin is a dipeptidyl peptidase 4-(DPP-4) inhibitor with glucose controlling capabilities that was effectively used for treating diabetes in the past. However, the oral administration of this drug caused such severe side effects that it was removed from the market.
Rekha Pathak, Manisha Swamy, Kavita Varma Shukla   +2 more
openaire   +2 more sources

Bioequivalence Study of a New Generic Fixed-Dose Combination of Sitagliptin (100 mg) and Glimepiride (2 mg) in Healthy Adult Volunteers under Fasting Condition

Chronicle of Diabetes Research and Practice
Introduction: The present study evaluated the bioequivalence of a fixed-dose combination (FDC) of sitagliptin and glimepiride with the originator reference product.
Prashant Kumthekar, Mihir Upadhyay, Koripalli S. Reddy, Sambasiva R. Puram, Basava S. Nallamekala   +4 more
doaj   +1 more source

Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®)

Dermatology Online Journal, 2012
Photosensitivity to sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is reported. No previous reports of photosensitivity to any DPP-4 inhibitors are known. Physical examination of the patient revealed edematous plaques confined to sun-exposed areas of the skin.
Stricklin, Sherea M, Stoecker, William V, Rader, Ryan K, Hood, Antoinette F, Litt, Jerome Z, Schuman, Thomas P   +5 more
openaire   +4 more sources

Sex‐Specific Regulation of Glycemic Homeostasis by Theabrownin from Pu‐erh Tea

Advanced Science, EarlyView.
Pu‐erh tea's key component, theabrownin (TB), lowers blood glucose in a sex‐specific manner. In females, estrogen boosts intestinal MUC2 production, which dramatically enhances TB's ability to inhibit the carbohydrate‐digesting enzyme α‐glucosidase.
Yang Li, Junliang Kuang, Dan Zheng, Jieyi Wang, Kun Ge, Chun Qu, Xiaojiao Zheng, Zhenxing Ren, Fengjie Huang, Mingliang Zhao, Yimin Sun, Huiheng Zhang, Keke Ding, Xixi Xia, Yajun Tang, Lu Liu, Jian Zhou, Fei Gao, Xiaohui Ma, Yongquan Xu, Guoxiang Xie, Aihua Zhao, Wei Jia   +22 more
wiley   +1 more source